

**AMENDMENTS TO THE CLAIMS**

This listing of the claims will replace all prior versions, and listings, of claims in this application.

1. **(Currently Amended)** A method of treating an inflammatory disorder in a patient in need thereof, wherein the method comprises comprising, the method comprising administering to said patient a pharmaceutical composition comprising a pharmaceutically acceptable carrier, wherein said composition comprises and at least one agent selected from the group consisting of: heme oxygenase-1 (HO-1), bilirubin, biliverdin, ferritin, iron, desferoxamine, salicylaldehyde isonicotinoyl hydrazone, iron dextran, or apoferritin, and an agent that induces endogenous HO-1 in the subject, wherein the composition is administered in an amount sufficient to treat the inflammatory disorder; and wherein the inflammatory disorder is localized in the gastrointestinal tract.

2. **(Currently Amended)** The method of claim 1, wherein the composition comprises treatment is inducing ferritin in the patient.

3. **(Cancelled)**

4. **(Currently Amended)** The method of claim 1, wherein the treatment is administering a pharmaceutical composition comprises an agent that induces endogenous comprising HO-1 to in the patient.

5. **(Currently Amended)** The method of claim 1, wherein the treatment is administering a pharmaceutical composition comprising comprises biliverdin to the patient.

6. **(Currently Amended)** The method of claim 5, wherein the pharmaceutical composition biliverdin is administered to the patient at a dosage of about 1 to 1000 micromoles/kg/day.

7. **(Previously Presented)** The method of claim 1, wherein the inflammatory disorder is ulcerative colitis.

8. **(Currently Amended)** The method of claim 1, wherein the ~~treatment is administering a pharmaceutical composition comprising~~ comprises bilirubin to the patient.

9. **(Currently Amended)** The method of claim 1, wherein the ~~treatment is administering a pharmaceutical composition comprising~~ comprises ferritin to the patient.

10. **(Currently Amended)** The method of claim 1, wherein the ~~treatment is administering a pharmaceutical composition comprising~~ comprises at least one of desferoxamine (DFO) or salicylaldehyde isonicotinoyl hydrazone (SIH) to the patient.

11. **(Currently Amended)** The method of claim 1, wherein the ~~treatment is administering a pharmaceutical composition comprising~~ comprises iron dextran to the patient.

12. **(Currently Amended)** The method of claim 1, wherein the ~~treatment is administering a pharmaceutical composition comprising~~ comprises apoferritin to the patient.

13. **(Currently Amended)** The method of claim 2, wherein the ~~ferritin is induced by administering~~ composition comprises iron to the patient.

14-16. **(Cancelled)**

17. **(Previously Presented)** The method of claim 1, wherein the inflammatory disorder is selected from the group consisting of: amoebic dysentery, bacillary dysentery, schistosomiasis, campylobacter enterocolitis, yersinia enterocolitis, enterobius vermicularis, radiation enterocolitis, ischaemic colitis, eosinophilic gastroenteritis, ulcerative colitis, indeterminate colitis, and Crohn's disease.

18. **(Previously Presented)** The method of claim 1, wherein the inflammatory disorder is ulcerative colitis.

19. **(Cancelled)**

20. **(Currently Amended)** The method of claim 1, further comprising the step of steps ~~of inducing HO-1 in the patient, and~~ administering a pharmaceutical composition comprising carbon monoxide to the patient.

21-62. **(Cancelled)**

63. **(New)** The method of claim 1, wherein the composition comprises at least two of the agents.

64. **(New)** The method of claim 63, wherein the composition comprises biliverdin and an agent that induces endogenous HO-1.

65. **(New)** The method of claim 63, wherein the composition comprises bilirubin and an agent that induces endogenous HO-1.

66. **(New)** The method of claim 1, wherein the at least one agent is administered orally.